Tracer library / [90Y]Y-DOTA-AR
[90Y]Y-DOTA-AR
Also written as [90Y]Y-DOTA-AR
- Radionuclide
- Y-90
- Modality
- —
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- Bombesin (GRPr) antagonist peptide conjugated to DOTA chelator
- Target / mechanism
- Gastrin-releasing peptide receptor (GRPr), bombesin receptor antagonist PMID 22080443
- Clinical application
- Prostate cancer (targeted radiotherapy of GRPr-positive tumors, preclinical mouse models) PMID 25840974
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | — | DOTA-AR | 28108545 2017 Clin Cancer Res 90Y-DOTA-AR was prepared according to the previously published protocol from our laboratory (17) |
Need this precursor?We can point you to suppliers for [90Y]Y-DOTA-AR, or handle the enquiry for you.
Get in touchNotes
Added at stage 39 (2026-09-27) from a reverse search of the PubMed corpus's own unattached articles (articles that named a real compound not yet in this reference): 2 article(s) found under this name, not yet individually researched. Target/mechanism, clinical application, indications, approval, modality, stage and production route are intentionally left empty. PMIDs: 22080443, 25840974. Stage set/updated at stage 39 from PMID 25840974: 'Mice bearing subcutaneous prostate cancer xenografts were injected with 0.74-18.5 MBq of the (90)Y-labeled GRPr antagonist DOTA-AR and underwent in vivo and ex vivo CLI at 1-48 h after injection.'.